TY - JOUR T1 - The impact of Type 2 diabetes in Parkinson’s disease JF - medRxiv DO - 10.1101/2021.10.21.21265308 SP - 2021.10.21.21265308 AU - Dilan Athauda AU - James Evans AU - Anna Wernick AU - Gurvir Virdi AU - Minee Liane-Choi AU - Michael Lawton AU - Nirosen Vijiaratnam AU - Christine Girges AU - Yoav Ben-Shlomo AU - Khalida Ismail AU - Huw Morris AU - Donald Grosset AU - Thomas Foltynie AU - Sonia Gandhi Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/26/2021.10.21.21265308.abstract N2 - Importance Type 2 diabetes (T2DM) is an established risk factor for developing Parkinson’s disease (PD) but its effect on disease progression is not well understood.Objective To examine the effects of co-morbid T2DM on Parkinson’s disease progression and quality of life.Design We analysed data from the Tracking Parkinson’s study, a large multi-centre prospective study in the UK.Participants The study included 1930 adults with recent onset PD, recruited between February 2012 and May 2014, and followed up regularly thereafter.Exposure A diagnosis of pre-existing T2DM was based on self-report at baseline. After controlling for confounders, an evaluation of how T2DM affects PD was performed by comparing symptom severity scores; and analyses using multivariable mixed models was used to determine the effects of T2DM on Parkinson’s disease progression.Main Outcomes and Measures The impact of T2DM on Parkinson’s disease severity was derived from scores collected using the Movement Disorders Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), Non-Motor Symptoms Scale (NMSS), Montreal Cognitive Assessment (MoCA), Questionnaire for impulsive-compulsive disorders in PD (QUIP), Leeds Anxiety and Depression Scale (LADS), and Schwab and England ADL scale.Results We identified 167 (8.7%) patients with PD and T2DM (PD+T2DM) and 1763 (91.3%) with PD without T2DM (PD). Patients with T2DM had more severe motor symptoms, as assessed by MDS-UPDS III 25.8 (0.9) vs 22.5 (0.3) p=0.002, had significantly faster motor symptom progression over time (p=0.012), and T2DM was an independent predictor for the development of substantial gait impairment (HR 1.55, CI 1.07-2.23, p=0.020). Patients were more likely to have loss of independence (OR 2.08, CI 1.34-3.25, p=0.001); and depression (OR 1.62, CI 1.10-2.39, p=0.015), and developed worsening mood (p=0.041) over time compared to the PD group. T2DM was also an independent predictor for the development mild cognitive impairment (HR 1.7, CI 1.24-2.51, p=0.002) over timeConclusions and relevance T2DM is associated with faster disease progression in PD, highlighting an interaction between these two diseases. As it is a potentially modifiable, metabolic state, with multiple peripheral and central targets for intervention, it may represent a target for ameliorating parkinsonian symptoms, and progression to disability and dementia.Question What is the impact of Type 2 diabetes on Parkinson’s disease progression?Findings In this prospective study of 1930 patients with recent onset PD, T2DM is an independent risk factor for more severe motor features, non-motor symptoms, and poorer quality of life; and importantly is associated with faster motor and non-motor symptom progression, and increases the risk of developing cognitive impairment.Meaning T2DM is identified as a new factor that alters Parkinson’s disease progression. T2DM predicts both motor and non-motor symptom progression in PD and is associated with poorer quality of life, highlighting an interaction of two chronic disease states. This highlights a particular need for improved treatment in this subgroup of patients with Parkinson’s.Competing Interest StatementDA received honoraria from Bial Pharma and grant funding from CureParkinson's, Parkinson's UK and NIHR, outside of submitted work. NV has received unconditional educational grants from IPSEN and Biogen, travel grants from IPSEN, AbbVie and honorarium from AbbVie and STADA and served on advisory boards for Abbvie and Brittania outside of the submitted work. YB-S has received grant funding from the MRC, NIHR, Parkinson's UK, NIH and ESRC. HM reports paid consultancy from Biogen, UCB, Abbvie, Denali, Biohaven, Lundbeck; lecture fees/honoraria from Biogen, UCB, C4X Discovery, GE‐Healthcare, Wellcome Trust, Movement Disorders Society; Research Grants from Parkinson's UK, Cure Parkinson's Trust, PSP Association, CBD Solutions, Drake Foundation, Medical Research Council. DG received honoraria from Bial Pharma, Merz Pharma, and consultancy fees from The GM Clinic, Glasgow. TF has received honoraria from Profile Pharma, BIAL, AbbVie, Genus, Medtronic, and St Jude Medical, outside the submitted work. All other authors report no other interests. Role of the funding source Tracking Parkinson's is primarily funded and supported by Parkinson's UK. It is supported by the National Institute for Health Research (NIHR) Dementias and Neurodegenerative Diseases Research Network (DeNDRoN). This research was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. The UCL Movement Disorders Centre is supported by the Edmond J. Safra Philanthropic Foundation. Funding StatementTracking Parkinson's is primarily funded and supported by Parkinson's UK. It is supported by the National Institute for Health Research (NIHR) Dementias and Neurodegenerative Diseases Research Network (DeNDRoN). This research was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. The UCL Movement Disorders Centre is supported by the Edmond J. Safra Philanthropic Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data was analysed from the Tracking Parkinson's, a long-term observational study into PD, which can obtained upon request from the Tracking Parkinson's committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript ER -